Doctors say active monitoring, hormone therapy and newer focal treatments are reshaping care decisions for men.

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

Ultrahypofractionated radiotherapy yields non-inferior 10-year survival outcomes compared to conventional treatment in ...

The issues affecting you. Revealed. Explained. Discussed. Now on WGAL 8 InFocus. Hello, I'm Susan Shapiro. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime. The American ...

Erleada shows consistent 24-month overall survival in real-world settings and the TITAN trial for metastatic castration-sensitive prostate cancer. Erleada reduces the risk of death by 23% compared to ...

While prostate cancer recurrence is a major cause of death in patients receiving localized treatment, there are other significant causes of mortality. While prostate cancer progression or recurrence ...

Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes. HealthDay News — Men with nonmetastatic prostate cancer receiving ...

As we gear up to observe World Cancer Day 2026 under the theme 'United by Unique', let's take a look at the stages of ...

Obesity Tied to Risk of Prostate Cancer After Negative Biopsy No correlation seen for high levels of metabolic factors and risk of prostate cancer Metabolic factors are not associated with the risk of ...

Giles Turner, from Brighton, is one of the men who could benefit from the drug Men with aggressive prostate cancer should be given a drug that halves their risk of death, experts have urged the NHS.